Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
Source: SeekingAlpha
2026-03-12 13:33:26 ET
Thesis
Codexis, Inc. ( CDXS ) has just reported a pretty strong end-of-year financial result. Revenue hit $38.9 million for the quarter, up about 81% year-over-year, and beat the consensus by about $3.1 million. Revenue was mainly helped out by a technology transfer agreement with Merck & Co. The company also showed us $9.6 million in net income compared with a $10.4 million loss in 4Q24, with product gross margin improving to 65%....
Read the full article on Seeking Alpha
For further details see:
Codexis Posts Strong Q4, Eyes siRNA Market With ECO Synthesis Platform
Codexis Inc.
NASDAQ: CDXS
CDXS Trading
-0.68% G/L:
$1.45 Last:
527,577 Volume:
$1.48 Open:
CDXS Latest News
May 20, 2026 09:00:00 am
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
$116,066,832
79,756,430
0.15%
40
N/A
Biotechnology & Life Sciences
Healthcare
US
Redwood City
